Serum antibody response to active infection with Cryptococcus neoformans and its varieties in immunocompetent subjects

Medical Mycology

Volumn 34, Issue 3, 1996, Pages 187-193

  Speed, B R ^a   Kaldor, J ^a   Cairns, B ^a   Pegorer, M ^a  

^a FAIRFIELD HOSPITAL   (Australia)

Author keywords

antibody; C. neoformans; cryptococcosis; variety

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; SEROEPIDEMIOLOGY; SERUM;

ADULT; ANTIBODIES, FUNGAL; ANTIGENS, FUNGAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; HUMANS; IMMUNOCOMPETENCE; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; TIME FACTORS;

EID: 80051528846     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/02681219680000311     Document Type: Article

References (23)

1. Zuger A, Louie E, Holzman RS, Simerkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104: 234-40.
2. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptυœccus neoformans. Clin Infect Dìs 1995; 21: 28-34.
3. Kaufman L, Blumer S. Value and interpretation of serological tests for the diagnosis of cryptococcosis. App Microbil 1968; 16: 1907-12.
4. Murphy JW. Cryptococcosis. In: Cox RA, ed. Immunology of the Fungal Diseases. CRC Press, Boca Raton, FL, 1989: 94-138.
5. Miller MF, Mitchell TG, Storkus WJ, Dawson JR. Human natural killer cells do not inhibit growth of Cryptocoecus neoformans in the absence of antibody. Infect Immun 1990; 58: 639-45. (Pubitemid 20072625)
6. Mukherjee S, Lee SC, Casadevall A. Antibodies to Cryptocoecus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun 1995; 63: 573-9.
7. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987; 55: 749-52. (Pubitemid 17021971)
8. Zebedee SL, Koduri RK, Mukherjee J, et al. Mouse-human ¡mmunoglobulin Gl chimerc antibodies with activities against Cryptocoecus neoformans. Antimicrυb Agents Chemother 1994; 38: 1507-14. (Pubitemid 24203560)
9. Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptocoecus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimiero? Agents Chemυther 1994; 38: 580-7. (Pubitemid 24072252)
10. Henderson DK, Bennett JE, Huber MA. Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis. J Clin Invest 1982; 69: 1185-90. (Pubitemid 12115683)
11. Scott EN, Felton FG, Muchmore HG. Development of an enzyme immunoassay for cryptococcal antibody. Mycopathohgia 1980; 70: 55-9. (Pubitemid 10115142)
12. Reiss E, Cherniak R, Eby R, Kaufman L. Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neofυrmans. Diagn Immunol 1984; 2: 109-15. (Pubitemid 15189763)
13. Houpt DC, Pfrommer GST, Young BJ, Larson TA, Kozel TR. Occurrences, immunoglobuhn classes and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoormans glucuronoxylomannan. Infect Immun 1994; 62: 2857-64. (Pubitemid 24203971)
14. Gordon MA, Vedder DK. Serologic tests in diagnosis and prognosis of cryptococcosis. JAMA 1966; 197: 961-70.
15. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neofυrmans. Am J Epidemiol 1984; 120: 123-30. (Pubitemid 14076734)
16. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neojormans var. gattii. J Clin Microbiol 1990; 28: 2-9.
17. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20: 611-16.
18. Speed BR, Kaldor J. Cryptococcosis in Melbourne. In: Program and Abstracts, Australasian Society for Infectious Diseases 1984.
19. Asznowicz R, Newton-John H, Kaldor J. Value of latex test in cryptococcal meningitis. Med J Aust 1979; 1: 347-9. (Pubitemid 9219807)
20. Speed BR, Cairns B, Kaldor J. The seroepidemiology of Cryptococcus neoormans utilising class-specific antibodies detected by enzyme immunoassay. In: Program and Abstracts, Second International Conference on Cryptococcus and Cryptococcosis 1993, Milan. Milan, Organizing Committee, 1993: P2-6 (abstract).
21. Bindschadler DD, Bennett JE. Serology of human cryptococcosis. Ann Int Med 1968; 69: 45-52.
22. Kaldor J, Asznowicz R, Buist DGP. Latex agglutination in diagnosis of bacterial infections with special reference to patients with meningitis and septicaemia. Am J Clin Pathol 1977; 68: 284-9. (Pubitemid 8140330)
23. Dromer F, Aucouturier P, Clauvel JP, Saimot G, Yeni P. Cryptococcus neoormans antibody levels in patients with AIDS. S('and J Infect Dis 1988; 20: 283-5.